{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T18:12:28Z","timestamp":1783793548325,"version":"3.55.0"},"reference-count":43,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/N013638\/1"],"award-info":[{"award-number":["MR\/N013638\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Stroke prevention guidance for patients with atrial fibrillation (AF) uses evidence generated from randomised controlled trials (RCTs). However, applicability to patient groups excluded from trials remains unknown. Real-world patient data provide an opportunity to evaluate outcomes in a trial analogous population of direct oral anticoagulants (DOACs) users and in patients otherwise excluded from RCTs; however, there remains uncertainty on the validity of methods and suitability of the data.<\/jats:p>\n<jats:p>Successful reference trial emulation can support the generation of evidence around treatment effects in groups excluded or underrepresented in trials.<\/jats:p>\n<jats:p>We used linked United Kingdom primary care data to investigate whether we could emulate the pivotal ARISTOTLE trial (apixaban versus warfarin) and extend the analysis to investigate the impact of warfarin time in therapeutic range (TTR) on results.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods and findings<\/jats:title>\n<jats:p>Patients with AF in the UK Clinical Practice Research Datalink (CPRD Aurum) prescribed apixaban or warfarin from 1 January 2013 to 31 July 2019 were selected. ARISTOTLE eligibility criteria were applied to this population and matched to the RCT apixaban arm on baseline characteristics creating a trial-analogous apixaban cohort; this was propensity-score matched to warfarin users in the CPRD Aurum. ARISTOTLE outcomes were assessed using Cox proportional hazards regression stratified by prior warfarin exposure status during 2.5 years of patient follow-up and results benchmarked against the trial results before treatment effectiveness was further evaluated based on (warfarin) TTR.<\/jats:p>\n<jats:p>The dataset comprised 8,734 apixaban users and propensity-score matched 8,734 warfarin users. Results [hazard ratio (95% confidence interval)] confirmed apixaban noninferiority for stroke or systemic embolism (SE) [CPRD 0.98 (0.82,1.19) versus trial 0.79 (0.66,0.95)] and death from any cause [CPRD 1.03 (0.93,1.14) versus trial 0.89 (0.80,0.998)] but did not indicate apixaban superiority. Absolute event rates for stroke\/SE were similar for apixaban in CPRD Aurum and ARISTOTLE (1.27%\/year), whereas a lower event rate was observed for warfarin (CPRD Aurum 1.29%\/year, ARISTOTLE 1.60%\/year).<\/jats:p>\n<jats:p>Analysis by TTR suggested similar effectiveness of apixaban compared with poorly controlled warfarin (TTR &lt; 0.75) for stroke\/SE [0.91 (0.73, 1.14)], all-cause death [0.94 (0.84, 1.06)], and superiority for major bleeding [0.74 (0.63, 0.86)]. However, when compared with well-controlled warfarin (TTR \u2265 0.75), apixaban was associated with an increased hazard for all-cause death [1.20 (1.04, 1.37)], and there was no significant benefit for major bleeding [1.08 (0.90, 1.30)]. The main limitation of the study\u2019s methodology are the risk of residual confounding, channelling bias and attrition bias in the warfarin arm, and selection bias and misclassification in the analysis by TTR.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Analysis of noninterventional data generated results demonstrating noninferiority of apixaban versus warfarin consistent with prespecified benchmarking criteria. Unlike in ARISTOTLE, superiority of apixaban versus warfarin was not seen, possible due to the lower proportion of Asian patients and higher proportion of patients with well-controlled warfarin compared to ARISTOTLE. This methodological template can be used to investigate treatment effects of oral anticoagulants in patient groups excluded from or underrepresented in trials and provides a framework that can be adapted to investigate treatment effects for other conditions.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pmed.1004377","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T17:29:59Z","timestamp":1724952599000},"page":"e1004377","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of oral anticoagulants for stroke prevention in atrial fibrillation using the UK clinical practice research Datalink Aurum: A reference trial (ARISTOTLE) emulation study"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9427-9468","authenticated-orcid":true,"given":"Emma Maud","family":"Powell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2040-1763","authenticated-orcid":true,"given":"Usha","family":"Gungabissoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7194-2615","authenticated-orcid":true,"given":"John","family":"Tazare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9168-6022","authenticated-orcid":true,"given":"Liam","family":"Smeeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2565-8525","authenticated-orcid":true,"given":"Paris J.","family":"Baptiste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2812-7086","authenticated-orcid":true,"given":"Turki M.","family":"Bin Hammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8618-7333","authenticated-orcid":true,"given":"Angel Y. S.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8970-1406","authenticated-orcid":true,"given":"Ian J.","family":"Douglas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2335-9641","authenticated-orcid":true,"given":"Kevin","family":"Wing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,8,29]]},"reference":[{"issue":"1","key":"pmed.1004377.ref001","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1136\/heartjnl-2018-312977","article-title":"Prevalence and treatment of atrial fibrillation in UK general practice from 2000 to 2016","volume":"105","author":"NJ Adderley","year":"2019","journal-title":"Heart"},{"issue":"8","key":"pmed.1004377.ref002","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: the Framingham Study","volume":"22","author":"PA Wolf","year":"1991","journal-title":"Stroke"},{"issue":"9","key":"pmed.1004377.ref003","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1161\/STROKEAHA.114.006070","article-title":"High prevalence of atrial fibrillation among patients with ischemic stroke","volume":"45","author":"L Friberg","year":"2014","journal-title":"Stroke"},{"issue":"5","key":"pmed.1004377.ref004","first-page":"1279","article-title":"Clinical and Economic Implications of AF Related Stroke","volume":"8","author":"AN Ali","year":"2016","journal-title":"J Atr Fibrillation"},{"issue":"4","key":"pmed.1004377.ref005","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1159\/000343667","article-title":"The prevalence, impact and economic implications of atrial fibrillation in stroke: what progress has been made?","volume":"40","author":"NE Andrew","year":"2013","journal-title":"Neuroepidemiology"},{"key":"pmed.1004377.ref006","first-page":"A32","article-title":"053 Factors affecting quality of warfarin anticoagulation in patients with atrial fibrillation: insights from affirm","volume":"98","author":"S Apostolakis","year":"2012","journal-title":"Heart"},{"issue":"11","key":"pmed.1004377.ref007","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"CB Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"pmed.1004377.ref008","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) Assessment report Eliquis apixaban. Procedure No.:EMEA\/H\/C\/002148\/X\/04\/G. EMA\/641505\/2012, 2012, page 35. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/eliquis-h-c-2148-x-0004-g-epar-assessment-report-extension_en.pdf"},{"key":"pmed.1004377.ref009","unstructured":"National Institute for Health and Clinical Excellence. Premeeting briefing. Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation. Issue date: November 2012. Available from: https:\/\/www.nice.org.uk\/guidance\/ta275\/documents\/stroke-and-systemic-embolism-prevention-nonvalvular-atrial-fibrillation-apixaban-premeeting-briefing2"},{"issue":"10","key":"pmed.1004377.ref010","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1161\/CIRCULATIONAHA.120.051718","article-title":"Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative","volume":"143","author":"JM Franklin","year":"2021","journal-title":"Circulation"},{"issue":"3","key":"pmed.1004377.ref011","doi-asserted-by":"crossref","first-page":"2001586","DOI":"10.1183\/13993003.01586-2020","article-title":"Real world effects of COPD medications: a cohort study with validation against results from randomised controlled trials","volume":"57","author":"K Wing","year":"2021","journal-title":"Eur Respir J"},{"issue":"5","key":"pmed.1004377.ref012","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1097\/EDE.0000000000001231","article-title":"Benchmarking Observational Methods by Comparing Randomized Trials and Their Emulations","volume":"31","author":"IJ Dahabreh","year":"2020","journal-title":"Epidemiology"},{"key":"pmed.1004377.ref013","doi-asserted-by":"crossref","unstructured":"Baptiste PJ, Wong AYS, Schultze A, Clase CM, Leyrat C, Williamson E, et al. Comparative effectiveness of ARB and ACEi for cardiovascular outcomes and risk of angioedema among different ethnic groups in England: an analysis in the UK Clinical Practice Research Datalink with emulation of a reference trial (ONTARGET). medRxiv [Preprint]. 2024. doi: 10.1101\/2024.01.17.24301397","DOI":"10.1101\/2024.01.17.24301397"},{"key":"pmed.1004377.ref014","doi-asserted-by":"crossref","first-page":"e042947","DOI":"10.1136\/bmjopen-2020-042947","article-title":"Real-world effects of medications for stroke prevention in atrial fibrillation: protocol for a UK population-based non-interventional cohort study with validation against randomized trial results","volume":"11","author":"EM Powell","year":"2021","journal-title":"BMJ Open"},{"issue":"6","key":"pmed.1004377.ref015","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1093\/ije\/dyz034","article-title":"Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum","volume":"48","author":"A Wolf","year":"2019","journal-title":"Int J Epidemiol"},{"key":"pmed.1004377.ref016","unstructured":"Rose M, Beasley N. Center for Drug Evaluation and Research Application number: 202155Orig1s000 MEDICAL REVIEW(S). Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/202155Orig1s000TOC.cfm"},{"issue":"46","key":"pmed.1004377.ref017","first-page":"3268","article-title":"Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial","volume":"36","author":"D Vinereanu","year":"2015","journal-title":"Eur Heart J"},{"issue":"28","key":"pmed.1004377.ref018","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1093\/eurheartj\/ehu046","article-title":"Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial","volume":"35","author":"S Halvorsen","year":"2014","journal-title":"Eur Heart J"},{"issue":"1","key":"pmed.1004377.ref019","first-page":"1","article-title":"Causal Inference without Balance Checking: Coarsened Exact Matching Political Analysis","volume":"20","author":"SM Iacus","year":"2012"},{"issue":"4","key":"pmed.1004377.ref020","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/pds.4107","article-title":"Prevalent new-user cohort designs for comparative drug effect studies by time-conditional propensity scores","volume":"26","author":"S Suissa","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"pmed.1004377.ref021","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/pds.5446","article-title":"Alternative analytic and matching approaches for the prevalent new-user design: A simulation study","volume":"31","author":"M Webster-Clark","year":"2022","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"pmed.1004377.ref022","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/bimj.200810488","article-title":"Some methods of propensity-score matching had superior performance to others: results of an empirical Investigation and Monte Carlo simulations","volume":"51","author":"P.C. Austin","year":"2009","journal-title":"Biom J"},{"issue":"10","key":"pmed.1004377.ref023","doi-asserted-by":"crossref","first-page":"e0140533","DOI":"10.1371\/journal.pone.0140533","article-title":"Accuracy of Electronic Health Record Data for Identifying Stroke Cases in Large-Scale Epidemiological Studies: A Systematic Review from the UK Biobank Stroke Outcomes Group","volume":"10","author":"UK Biobank Stroke Outcomes Group","year":"2015","journal-title":"PLoS ONE"},{"issue":"24","key":"pmed.1004377.ref024","doi-asserted-by":"crossref","first-page":"4306","DOI":"10.1002\/sim.6276","article-title":"The use of bootstrapping when using propensity-score matching without replacement: A simulation study","volume":"33","author":"P.C Austin","year":"2014","journal-title":"Stat Med"},{"issue":"538","key":"pmed.1004377.ref025","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1080\/01621459.2020.1840383","article-title":"Robust Post-Matching Inference","volume":"117","author":"A. Abadie","year":"2022","journal-title":"J Am Stat Assoc"},{"issue":"1","key":"pmed.1004377.ref026","first-page":"143","article-title":"Addressing the issue of channeling bias in observational studies with propensity scores analysis","volume":"2","author":"FS Lobo","year":"2006","journal-title":"Res SocialAdm Pharm"},{"issue":"1","key":"pmed.1004377.ref027","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects","volume":"70","author":"PR Rosenbaum","year":"1983","journal-title":"Biometrika"},{"issue":"11","key":"pmed.1004377.ref028","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1002\/sim.8503","article-title":"Propensity scores using missingness pattern information: a practical guide","volume":"39","author":"HA Blake","year":"2020","journal-title":"Stat Med"},{"key":"pmed.1004377.ref029","doi-asserted-by":"crossref","first-page":"k2505","DOI":"10.1136\/bmj.k2505","article-title":"Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care","volume":"362","author":"Y Vinogradova","year":"2018","journal-title":"BMJ"},{"issue":"353","key":"pmed.1004377.ref030","doi-asserted-by":"crossref","first-page":"i3189","DOI":"10.1136\/bmj.i3189","article-title":"Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study","volume":"16","author":"TB Larsen","year":"2016","journal-title":"BMJ"},{"issue":"6","key":"pmed.1004377.ref031","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1160\/TH17-01-0068","article-title":"Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in \u201creal-world\u201d clinical practice. A propensity-matched analysis of 76,940 patients","volume":"117","author":"XS Li","year":"2017","journal-title":"Thromb Haemost"},{"issue":"1","key":"pmed.1004377.ref032","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1161\/STROKEAHA.117.018395","article-title":"Real-World Use of Apixaban for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis","volume":"49","author":"M Proietti","year":"2018","journal-title":"Stroke"},{"key":"pmed.1004377.ref033","unstructured":"Franklin J, Brigham and Women\u2019s Hospital. Replication of the ARISTOTLE Anticoagulant Trial in Healthcare Claims Data. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04593030"},{"issue":"16","key":"pmed.1004377.ref034","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1001\/jama.2023.4221","article-title":"Emulation of Randomized Clinical Trials With Nonrandomized Databse Analyses: Results of 32 Clinical Trials","volume":"329","author":"RCT-DUPLICATE initiative","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"pmed.1004377.ref035","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ahj.2015.03.017","article-title":"Patients\u2019 time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry","volume":"170","author":"SD Pokorney","year":"2015","journal-title":"Am Heart J"},{"issue":"13","key":"pmed.1004377.ref036","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1001\/jama.2017.13883","article-title":"Association Between Use of Non-Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation","volume":"318","author":"SH Chang","year":"2017","journal-title":"JAMA"},{"issue":"4","key":"pmed.1004377.ref037","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1001\/jamainternmed.2018.7816","article-title":"Association of Adding Aspirin to Warfarin Therapy Without an Apparent Indication With Bleeding and Other Adverse Events","volume":"179","author":"JK Schaefer","year":"2019","journal-title":"JAMA Intern Med"},{"key":"pmed.1004377.ref038","first-page":"101016","article-title":"Efficacy and safety of direct oral anticoagulants with and without Aspirin: A systematic review and Meta-analysis","volume":"40","author":"T Almas","year":"2022","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"5","key":"pmed.1004377.ref039","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrcardio.2014.22","article-title":"Oral anticoagulants for Asian patients with atrial fibrillation","volume":"11","author":"I Sabir","year":"2014","journal-title":"Nat Rev Cardiol"},{"issue":"4","key":"pmed.1004377.ref040","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1055\/s-0040-1718729","article-title":"The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease","volume":"121","author":"HK Kim","year":"2021","journal-title":"Thromb Haemost"},{"issue":"3","key":"pmed.1004377.ref041","first-page":"356","article-title":"South Asian ethnicity is associated with a lower prevalence of atrial fibrillation despite greater prevalence of established risk factors: a population-based study in Bradford Metropolitan District","volume":"19","author":"RG Gillott","year":"2017","journal-title":"Europace"},{"key":"pmed.1004377.ref042","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12963-023-00302-0","article-title":"Completeness, agreement, and representativeness of ethnicity recording in the United Kingdom\u2019s Clinical Practice Research Datalink (CPRD) and linked Hospital Episode Statistics (HES)","volume":"21","author":"SI Shiekh","year":"2023","journal-title":"Popul Health Metr"},{"issue":"2","key":"pmed.1004377.ref043","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/heartjnl-2019-315307","article-title":"Adherence and persistence to direct oral anticoagulants in atrial fibrillation: a population-based study","volume":"106","author":"A Banerjee","year":"2020","journal-title":"Heart"}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004377","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T17:30:24Z","timestamp":1724952624000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,29]]},"references-count":43,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1004377","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,29]]}}}